Drug intelligence / Profile preview

NM81

Development stage: Preclinical
Lead developer: Numab Therapeutics
Modality: Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

NM81 is a potential first-in-class multispecific antibody being developed for the treatment of inflammatory bowel disease (IBD). Developed by Numab Therapeutics using its proprietary MATCH™ platform, NM81 is designed to simultaneously target multiple pathways involved in the pathogenesis of IBD, potentially offering improved efficacy over conventional monoclonal antibodies. The program is being advanced under a licensing and co-development agreement with Kaken Pharmaceutical, which is responsible for funding the preclinical and clinical development of the candidate through clinical proof of concept.

Beyond the preview

Go deeper on NM81.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NM81.

Explore the full profile